Passa al contenuto
Merck
Tutte le immagini(2)

Documenti

38956

Supelco

Simvastatin

analytical standard

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(2)

About This Item

Formula empirica (notazione di Hill):
C25H38O5
Numero CAS:
79902-63-9
Peso molecolare:
418.57
Numero MDL:
MFCD00072007
Codice UNSPSC:
41116107
ID PubChem:
329755810
NACRES:
NA.24

Grado

analytical standard

Livello qualitativo

100

Saggio

≥98.0% (HPLC)

Attività ottica

[α]/D +275±25°, c = 1 in acetonitrile

Durata

limited shelf life, expiry date on the label

tecniche

HPLC: suitable
gas chromatography (GC): suitable

Impurezze

≤0.5% water

Punto di fusione

127-132 °C (lit.)

applicazioni

forensics and toxicology
pharmaceutical (small molecule)
veterinary

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)OC(=O)C(C)(C)CC

InChI

1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
RYMZZMVNJRMUDD-HGQWONQESA-N

Informazioni sul gene

human ... HMGCR(3156)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Azioni biochim/fisiol

Simvastatin is a specific inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early step in cholesterol biosynthesis. It is used in the treatment of hypercholesterolemia, as it reduces levels of low-density lipoproteins and triglycerides, and raises high-density lipoprotein levels. Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding β-hydroxyacid, and can be activated prior to use with NaOH in EtOH treatment. It is a synthetic analog of lovastatin (Cat. No. M2147).

Pittogrammi

Health hazard
GHS08

Avvertenze

Warning

Indicazioni di pericolo

H361d

Classi di pericolo

Repr. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number
BCCG4003
BCCC8162
BCCB9688
BCCB7519
BCCB3929

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

Tenivastatin ammonium salt analytical standard

Supelco

07363

Tenivastatin ammonium salt

Lovastatin European Pharmacopoeia (EP) Reference Standard

L0790000

Lovastatin

Mevastatin ≥98% (HPLC), powder or crystals

Sigma-Aldrich

M2537

Mevastatin

Lovastatin Lovastatin, CAS 75330-75-5, is an anti-hypercholesterolemic agent that inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.

Sigma-Aldrich

438185

Lovastatin

Mevinolina ≥98% (HPLC)

Sigma-Aldrich

M2147

Mevinolina

Fluvastatin sodium hydrate ≥98% (HPLC)

Sigma-Aldrich

SML0038

Fluvastatin sodium hydrate

A Marot et al.
Acta clinica Belgica, 66(2), 134-136 (2011-06-03)
Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy. Predisposing factors include comorbidities and the concomitant use of cytochrome P-450 (CYP) 3A4 inhibitors. We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone
L B Ramsey et al.
Clinical pharmacology and therapeutics, 96(4), 423-428 (2014-06-12)
Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association
Gerard J Criner et al.
The New England journal of medicine, 370(23), 2201-2210 (2014-05-20)
Retrospective studies have shown that statins decrease the rate and severity of exacerbations, the rate of hospitalization, and mortality in chronic obstructive pulmonary disease (COPD). We prospectively studied the efficacy of simvastatin in preventing exacerbations in a large, multicenter, randomized
Stephen J Nicholls et al.
The American journal of cardiology, 105(1), 69-76 (2010-01-28)
Statins are the most commonly prescribed agents for lowering levels of low-density lipoprotein (LDL) cholesterol. Although dose-dependent reductions in levels of atherogenic lipids are observed with all statins, the impact of increasing dose has not been fully elucidated. An individual
Daniel F McAuley et al.
The New England journal of medicine, 371(18), 1695-1703 (2014-10-01)
Studies in animals and in vitro and phase 2 studies in humans suggest that statins may be beneficial in the treatment of the acute respiratory distress syndrome (ARDS). This study tested the hypothesis that treatment with simvastatin would improve clinical
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.